This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1568 entries already.
Italian pharma group Chiesi has struck a near‑US$1.9bn deal to acquire KalVista Pharmaceuticals, bringing the US biotech’s first‑in‑class oral treatment for hereditary angioedema into its rare‑disease portfolio.
Belgian Coultreon Biopharma has raised US$125m in a big‑pharma‑backed Series A round to push its first‑in‑class SIK3 inhibitor into Phase II after an ongoing Phase I programme in autoimmune disease
Pan-European private‑equity firm Astorg has agreed to acquire Thermo Fisher Scientific’s global microbiology business for about US$1.08bn, carving it out into a standalone platform focused on antimicrobial susceptibility testing and microbiology diagnostics. The investment is being made through Astorg VIII, the firm’s latest flagship buy‑out fund.
CureVac has filed a federal lawsuit accusing Moderna of patent infringement over its mRNA-based COVID-19 vaccine Spikevax. The German biotech claims that Moderna used its proprietary methods for stabilising messenger RNA without authorisation and is seeking monetary damages framed as royalties on Spikevax sales.
Evonik is investing €80 million in its fermentation plant in Slovakia, pushing the Group’s structural transformation forward with a major investment in biotechnology. Alongside spider‑silk proteins from Amsilk, the site is set to offer a broader CDMO portfolio for the pharmaceutical industry.
Kurma Partners has closed Biofund IV at €215 million, giving European biotech founders a meaningful new source of capital even though the vehicle came in below the €250 million target Kurma set when it launched the fund in October 2024. At first close, Kurma had raised €140 million and said Biofund IV would back 16 to 20 companies, building on the strategy it used in earlier funds.
CryptiVax-1001 is set to enter first-in-human testing in advanced high-grade serous ovarian cancer, a setting with few durable treatment options.
According to the WHO, one adult in six globally is affected by infertility, but beyond this statistic, infertility is best understood as a couple’s problem, even when the underlying biology sits with one partner. The way we currently handle infertility issues is more about bypassing biology through procedure, with in vitro fertilisation (IVF) as its backbone. But while IVF is indispensable, success rates still vary, pushing biotech to step in and find new solutions.
Swiss pharma giant Roche announced that its investigational BTK inhibitor fenebrutinib sharply reduced multiple sclerosis relapses in Phase III studies. However, death imbalances cloud the picture.
Belgian biopharma UCB has agreed to acquire clinical-stage biotech Neurona Therapeutics for up to US$1.15 billion, betting on a one-off cell therapy that aims to structurally repair the brains of people with drug-resistant epilepsy.